- Home
- KRKR vs BCDA Comparison
KRKR vs BCDA Comparison
Compare KRKR & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRKR
- BCDA
- Stock Information
- Founded
- KRKR 2010
- BCDA N/A
- Country
- KRKR China
- BCDA United States
- Employees
- KRKR N/A
- BCDA N/A
- Industry
- KRKR Business Services
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- KRKR Consumer Discretionary
- BCDA Health Care
- Exchange
- KRKR Nasdaq
- BCDA Nasdaq
- Market Cap
- KRKR 9.9M
- BCDA 11.3M
- IPO Year
- KRKR 2019
- BCDA N/A
- Fundamental
- Price
- KRKR $5.24
- BCDA $2.06
- Analyst Decision
- KRKR
- BCDA Strong Buy
- Analyst Count
- KRKR 0
- BCDA 1
- Target Price
- KRKR N/A
- BCDA $25.00
- AVG Volume (30 Days)
- KRKR 3.4K
- BCDA 62.9K
- Earning Date
- KRKR 09-19-2025
- BCDA 08-11-2025
- Dividend Yield
- KRKR N/A
- BCDA N/A
- EPS Growth
- KRKR N/A
- BCDA N/A
- EPS
- KRKR N/A
- BCDA N/A
- Revenue
- KRKR $31,657,328.00
- BCDA N/A
- Revenue This Year
- KRKR $182.55
- BCDA N/A
- Revenue Next Year
- KRKR N/A
- BCDA N/A
- P/E Ratio
- KRKR N/A
- BCDA N/A
- Revenue Growth
- KRKR N/A
- BCDA N/A
- 52 Week Low
- KRKR $2.76
- BCDA $1.63
- 52 Week High
- KRKR $12.99
- BCDA $3.26
- Technical
- Relative Strength Index (RSI)
- KRKR 55.86
- BCDA 56.99
- Support Level
- KRKR $4.42
- BCDA $1.90
- Resistance Level
- KRKR $5.10
- BCDA $1.99
- Average True Range (ATR)
- KRKR 0.26
- BCDA 0.08
- MACD
- KRKR 0.06
- BCDA 0.03
- Stochastic Oscillator
- KRKR 95.15
- BCDA 90.00
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).